SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as it joins a new government-backed federal initiative designed to accelerate advanced nuclear reactor deployment for AI data centers. Investors are closely monitoring the company's progress toward reactor criticality and potential isotope commercialization, though debates persist within the community regarding the company's valuation, dilution, and timeline for achieving meaningful revenue.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce is attracting significant attention as investors react to exceptional financial performance, raised profit guidance, and growing momentum in its Small Modular Reactor and defense segments. Community sentiment is largely bullish, with active discussions focused on the company's expanding order pipeline, hyperscaler data center partnerships, and its role in sovereign defense programs.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is facing heightened investor scrutiny as the broader nuclear energy sector navigates regulatory challenges and volatile price action. While the community remains divided over the company's long-term commercialization timeline, bullish participants are looking for catalysts like new project contracts and government investment to break the stock's current consolidation phase.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors monitor the upcoming CHMP regulatory review, with community sentiment fueled by bullish analyst price target adjustments and speculation regarding a potential buyout. Stakeholders are actively debating the impact of the pending EMA decision while focusing on the stock's tight float and institutional accumulation.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is facing increased scrutiny and volatility following reports of a significant treasury exploit that has pressured the token's market sentiment. While some community members remain focused on long-term accumulation, others are actively debating whether meme tokens have lost their fundamental appeal, leading to a polarizing environment between vocal bulls and skeptical critics.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently seeing significant investor anticipation as the market awaits top-line data from the Phase 3 IZAR-1 trial, which is expected to serve as a major catalyst for the stock. Community sentiment is deeply divided between long-term holders awaiting a potential buyout and skeptics focused on recent insider selling, leading to high-volume short interest and active debates regarding the company's valuation and the timing of clinical trial results.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as investors digest the impact of ongoing geopolitical disruptions in the Middle East, which continue to drive energy volatility and supply concerns. The community is actively debating the stock's role as an inflation hedge and data center power provider, while closely monitoring how potential shifts in crude oil pricing and supply-side developments will affect near-term earnings.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is currently being driven by a tug-of-war between aggressive AI infrastructure spending and heightened geopolitical tensions in the Middle East. Community sentiment remains polarized, with many traders actively debating whether to scale back leveraged positions due to volatility or to continue buying dips under the belief that AI fundamentals will ultimately outweigh macro headwinds.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to the company securing UAE marketing authorization for its lead immunotherapy, Anktiva, across both bladder and lung cancer indications, while the community remains hyper-focused on the company's global expansion strategy and the upcoming second-quarter earnings report. Despite this regulatory milestone, active discussion centers on the stock's high short interest and market volatility, with many investors debating whether current price action reflects a potential undervaluation or ongoing institutional suppression.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending as investors focus on the strong adoption of its oral Wegovy pill and positive EU regulatory momentum, while the company escalates legal action against Eli Lilly to challenge competitor advertising claims. Community sentiment is shifting toward a bullish stance as many market participants interpret recent price action and prescription growth as signs of a structural recovery and an attractive long-term valuation compared to sector peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top 3 Health Care Stocks You'll Regret Missing In Q2

Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold, according to Benzinga Pro. iRhythm, Procept Biorobotics, Anbio Biotechnology among lowest RSI values.read more...

Anbio Biotechnology (NASDAQ:NNNN) Shares Up 11.6% - Time to Buy?

Anbio Biotechnology (NASDAQ:NNNN) Trading Up 11.6% - What's Next...

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Down   - Should You Sell?

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Down - Should You Sell...

Anbio Biotechnology (NASDAQ:NNNN) Trading Down 5.5% - Here's What Happened

Anbio Biotechnology (NASDAQ:NNNN) Trading Down 5.5% - Here's Why...

Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio

Anbio Biotechnology reported strong 2025 results with sales of $8.65M. The company is diversifying away from COVID products.read more...

Anbio Biotechnology (NASDAQ:NNNN) Shares Up 4.4%  - Still a Buy?

Anbio Biotechnology (NASDAQ:NNNN) Trading Up 4.4% - Still a Buy...

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - Still a Buy?

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - What's Next...

Anbio Biotechnology (NASDAQ:NNNN) Stock Price Up 5.6% - Still a Buy?

Anbio Biotechnology (NASDAQ:NNNN) Trading 5.6% Higher - Here's What Happened...

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up   - Still a Buy?

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - Still a Buy...

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Down   - Time to Sell?

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany.

Anbio Biotechnology - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.90
Prev Close	$10.75
Open	$10.60
Dividend Yield	0.00%
50-Day Moving Average	$17.04
Beta	0.30
Avg. Volume	49,833.99
PE Ratio	60.48

52-Week High	$54.95
52-Week Low	$8.30
Market Capitalization	$1.42B
EPS (Annual)	$0.1646
Price to Book	12.27
Revenue Per Employee	$361,431.00

Feed

News

Sentiment

Fundamentals

Info